The demand for medical supplies soars worldwide in the fight against COVID-19, there is a parallel risk of substandard and counterfeit medicines in the global market.
Topics of Discussion:
• Safeguard the quality of biopharma & global initiatives in curbing falsified.
• The current state of science of immunology & clinical research of COVID 19
• The pharma supply chain after COVID -19
• Evaluating Pharma Amid COVID-19
• Regulatory framework amendments required to curb the substandard and falsified.